Revenue

EBITDA

Earnings

Price per share at the end of the period divided by the last reported earnings

Free Cash Flow

XOMA Corporation operates as a biotechnology royalty aggregator in Europe, the United States, and the Asia Pacific. The company engages in helping biotech companies for enhancing human health. It acquires the potential future economics associated with pre-commercial therapeutic candidates that have been licensed to pharmaceutical or biotechnology companies. The company focuses on early to mid-stage clinical assets primarily in Phase 1 and 2 with commercial sales potential that are licensed to partners. It has a portfolio with approximately 70 assets. XOMA Corporation was incorporated in 1981 and is headquartered in Emeryville, California.

XOMA Corporation

The significance of a company's longevity in the market

Years since IPO

Evaluation of recent trends and improvements in the company's revenue

Revenue Growth

Assessment of recent increases in earnings per share, indicating profitability

EPS Growth

Review of the company's ability to generate free cash flow over recent periods

FCF Growth

Analysis of Return on Equity, showing how effectively the company uses equity to generate profits

Examination of debt levels using Debt/Assets and Debt/EBITDA to ensure manageable leverage

Debt

NEW YORK, JAN. 8, 2026 /PRNEWSWIRE/ -- POMERANTZ LLP IS INVESTIGATING CLAIMS ON BEHALF OF INVESTORS OF XOMA ROYALTY CORPORATION ("XOMA" OR THE "COMPANY") (NASDAQ: XOMA).SUCH INVESTORS ARE ADVISED TO CONTACT DANIELLE PEYTON AT NEWACTION@POMLAW.COMOR 646-581-9980, EXT.

INVESTOR ALERT: POMERANTZ LAW FIRM INVESTIGATES CLAIMS ON BEHALF OF INVESTORS OF XOMA ROYALTY CORPORATION - XOMA

NEW YORK, JAN. 1, 2026 /PRNEWSWIRE/ -- POMERANTZ LLP IS INVESTIGATING CLAIMS ON BEHALF OF INVESTORS OF XOMA ROYALTY CORPORATION ("XOMA" OR THE "COMPANY") (NASDAQ: XOMA).SUCH INVESTORS ARE ADVISED TO CONTACT DANIELLE PEYTON AT NEWACTION@POMLAW.COMOR 646-581-9980, EXT.

EMERYVILLE, CALIF., DEC. 22, 2025 (GLOBE NEWSWIRE) -- XOMA ROYALTY CORPORATION (NASDAQ: XOMA), THE BIOTECH ROYALTY AGGREGATOR, TODAY ANNOUNCED ITS BOARD OF DIRECTORS HAS AUTHORIZED THE FOLLOWING CASH DIVIDENDS TO HOLDERS OF XOMA ROYALTY'S SERIES A AND SERIES B CUMULATIVE PREFERRED STOCK: HOLDERS OF THE 8.625% SERIES A CUMULATIVE PERPETUAL PREFERRED STOCK (NASDAQ: XOMAP) SHALL RECEIVE A CASH DIVIDEND EQUAL TO $0.53906 PER SHARE.

XOMA ROYALTY DECLARES QUARTERLY PREFERRED STOCK DIVIDENDS

- ACQUISITION PROVIDES XOMA ROYALTY WITH POTENTIAL MILESTONE AND ROYALTYPAYMENTS UNDER GENERATION BIO'S COLLABORATION WITH MODERNA -

XOMA ROYALTY ENTERS INTO AGREEMENT TO ACQUIRE GENERATION BIO

EMERYVILLE, CALIF., DEC. 05, 2025 (GLOBE NEWSWIRE) -- XOMA ROYALTY CORPORATION (XOMA ROYALTY) (NASDAQ: XOMA), THE BIOTECH ROYALTY AGGREGATOR, TODAY ANNOUNCED IT HAS SUCCESSFULLY COMPLETED ITS PREVIOUSLY ANNOUNCED ACQUISITION OF THE ENTIRE ISSUED AND TO BE ISSUED SHARE CAPITAL OF MURAL ONCOLOGY PLC (MURAL) (NASDAQ: MURA) (THE ACQUISITION) PURSUANT TO AN IRISH HIGH COURT SANCTIONED SCHEME OF ARRANGEMENT UNDER CHAPTER 1 OF PART 9 OF THE COMPANIES ACT 2014 OF IRELAND (THE SCHEME). MURAL SHAREHOLDERS RECEIVED $2.035 IN CASH PER SHARE (THE CONSIDERATION).

XOMA ROYALTY ANNOUNCES CLOSING OF TRANSACTION TO ACQUIRE MURAL ONCOLOGY PLC

WALTHAM, MASS. AND DUBLIN, DEC. 05, 2025 (GLOBE NEWSWIRE) -- MURAL ONCOLOGY PLC, (NASDAQ: MURA) (MURAL) ANNOUNCES THAT THE SCHEME OF ARRANGEMENT BETWEEN MURAL AND ITS SHAREHOLDERS UNDER CHAPTER 1 OF PART 9 OF THE COMPANIES ACT 2014 (THE SCHEME) PURSUANT TO WHICH XRA 5 CORP. (SUB), A WHOLLY-OWNED SUBSIDIARY OF XOMA ROYALTY CORPORATION (NASDAQ: XOMA) (XOMA ROYALTY) WILL ACQUIRE THE ENTIRE ISSUED AND TO BE ISSUED SHARE CAPITAL OF MURAL, BECAME EFFECTIVE TODAY, 5 DECEMBER 2025 (THE EFFECTIVE DATE).

MURAL ONCOLOGY ANNOUNCES EFFECTIVENESS OF SCHEME OF ARRANGEMENT AND COMPLETION OF ACQUISITION

WALTHAM, MASS. AND DUBLIN, DEC. 03, 2025 (GLOBE NEWSWIRE) -- MURAL ONCOLOGY PLC, (NASDAQ: MURA) (MURAL)ANNOUNCES THAT THE HIGH COURT OF IRELAND HAS TODAY SANCTIONED THE SCHEME OF ARRANGEMENT BETWEEN MURAL AND ITS SHAREHOLDERS UNDER CHAPTER 1 OF PART 9 OF THE COMPANIES ACT 2014 (THE SCHEME) PURSUANT TO WHICH XRA 5 CORP. (SUB), A WHOLLY-OWNED SUBSIDIARY OF XOMA ROYALTY CORPORATION (NASDAQ: XOMA) (XOMA ROYALTY), WILL ACQUIRE THE ENTIRE ISSUED AND TO BE ISSUED SHARE CAPITAL OF MURAL (THE ACQUISITION).

MURAL ONCOLOGY ANNOUNCES SANCTION OF THE SCHEME BY THE HIGH COURT

WALTHAM, MASS. AND DUBLIN, IRELAND, NOV. 26, 2025 (GLOBE NEWSWIRE) -- MURAL ONCOLOGY PLC (NASDAQ: MURA) (MURAL)ANNOUNCES THAT, IN ACCORDANCE WITH THE TERMS OF THE TRANSACTION AGREEMENT BETWEEN XOMA ROYALTY CORPORATION (NASDAQ: XOMA) (XOMA ROYALTY), XRA 5 CORP. (SUB) AND MURAL ANNOUNCED ON AUGUST 20, 2025 (THE TRANSACTION AGREEMENT), THE ADDITIONAL PRICE PER SHARE (AS DEFINED IN THE TRANSACTION AGREEMENT) HAS BEEN FINALLY DETERMINED IN ACCORDANCE WITH CLAUSE 2.4 OF THE TRANSACTION AGREEMENT AS $0.000. AS A RESULT, THE TOTAL CASH CONSIDERATION PAYABLE TO MURAL SHAREHOLDERS ON CLOSING OF THE ACQUISITION (AS DEFINED BELOW) WILL BE $2.035 IN CASH PER SHARE.

MURAL ONCOLOGY ANNOUNCES FINAL CASH CONSIDERATION PAYABLE ON CLOSING OF ACQUISITION BY XOMA ROYALTY

EMERYVILLE, CALIF., NOV. 21, 2025 (GLOBE NEWSWIRE) -- XOMA ROYALTY CORPORATION (XOMA ROYALTY) (NASDAQ: XOMA) TODAY ANNOUNCED IT HAS SUCCESSFULLY COMPLETED ITS PREVIOUSLY ANNOUNCED ACQUISITION OF ALL THE OUTSTANDING COMMON SHARES OF LAVA THERAPEUTICS N.V.

XOMA ROYALTY ANNOUNCES CLOSING OF TRANSACTIONS TO ACQUIRE LAVA THERAPEUTICS N.V.

BUSINESS DEVELOPMENT : SECURES ROYALTY ECONOMIC INTERESTS IN TWO EARLY STAGE PARTNERED ASSETS THROUGH XOMA ROYALTY'S ANNOUNCED EXPECTED ACQUISITION OF LAVA THERAPEUTICS.

XOMA ROYALTY REPORTS THIRD QUARTER AND YEAR TO DATE 2025 FINANCIAL RESULTS AND HIGHLIGHTS RECENT BUSINESS ACHIEVEMENTS

UTRECHT, THE NETHERLANDS AND PHILADELPHIA, NOV. 10, 2025 (GLOBE NEWSWIRE) -- LAVA THERAPEUTICS N.V. (LAVA) (NASDAQ: LVTX) TODAY ANNOUNCED A REMINDER TO LAVA SHAREHOLDERS RELATED TO THE PROPOSED TRANSACTION WITH XOMA ROYALTY CORPORATION (XOMA) (NASDAQ: XOMA).

XOMA Corporation

XOMA

Price

Financial Reports

No items found.

Press Releases

XOMA Corporation

XOMA.css-1jgtvd5{-webkit-user-select:none;-moz-user-select:none;-ms-user-select:none;user-select:none;width:1em;height:1em;overflow:hidden;display:inline-block;text-align:center;-webkit-flex-shrink:0;-ms-flex-negative:0;flex-shrink:0;font-size:1.5rem;}

Price

Financial Reports

No items found.

Press Releases

XOMA